Company intelligence / Profile preview

Matrixome

Osaka, Osaka, Japan

Ownership: Private
Development stage: Other

Overview

Matrixome does not develop its own therapeutics; it commercializes laminin-E8 fragment–based recombinant basement membrane proteins (iMatrix series) as cell culture substrates that support efficient, feeder-free culture and expansion of human pluripotent stem cells and other cell types, widely used in regenerative medicine and cell therapy research and manufacturing.

Therapeutic areas: Other
Modalities: Recombinant proteinBiologicNon-pharmacological therapy
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Matrixome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Matrixome.

Explore the full profile